Poor outcomes of early recurrent post-transplant bloodstream infection in living-donor liver transplant recipients

Eur J Clin Microbiol Infect Dis. 2021 Apr;40(4):771-778. doi: 10.1007/s10096-020-04074-5. Epub 2020 Oct 21.

Abstract

Bloodstream infection (BSI) is a common complication after living-donor liver transplantation (LDLT). Some patients develop recurrent BSIs. We evaluated the impacts of early recurrent BSIs (ER-BSIs) on outcomes in LDLT recipients. LDLT cases between 2008 and 2016 were included. Early BSI (E-BSI) was defined as a BSI event that occurred within 2 months after LDLT. ER-BSIs were defined as new-onset BSIs within 2 months due to another pathogen at a ≥ 48-h interval or a relapse of BSIs by the same pathogen at a ≥ 1-week interval, with negative cultures in between. The primary objective was evaluating the all-cause mortality of each group of LDLT recipients (90 days and 1 year). The secondary objectives were analyzing associated factors of each all-cause mortality and risk factors for early single BSI and ER-BSI. Among 727 LDLT recipients, 108 patients experienced 149 events of E-BSI with 170 isolated pathogens. Twenty-eight patients (25.9%, 28/108) experienced ER-BSI. The 1-year survival rates of patients without BSI, with early single BSI event, and with ER-BSIs were 92.4%, 81.3%, and 28.6%, respectively. ER-BSI was the most significant risk factor for 1-year mortality (adjusted HR = 5.31; 95% CI = 2.27-12.40). Intra-abdominal and/or biliary complications and early allograft dysfunction were risk factors for both early single BSI and ER-BSI. Interestingly, longer cold ischemic time and recipient operative time were associated with ER-BSI. LDLT recipients with ER-BSI showed very low survival rates accompanied by intra-abdominal complications. Clinicians should prevent BSI recurrence by being aware of intra-abdominal complications.

Keywords: Bacteremia; Fungemia; Living-donor liver transplantation; Mortality; Recurrence.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Bacteremia / microbiology*
  • Bacteria / classification
  • Bacteria / drug effects
  • Bacterial Infections / etiology*
  • Bacterial Infections / microbiology
  • Bacterial Infections / pathology
  • Drug Resistance, Multiple, Bacterial
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Liver Transplantation / adverse effects*
  • Living Donors*
  • Recurrence
  • Tacrolimus / therapeutic use
  • Treatment Outcome

Substances

  • Anti-Bacterial Agents
  • Immunosuppressive Agents
  • Tacrolimus